Product Details
| Product Name:
BIBF0775 |
CAS No.:
334951-90-5 |
| Purity:
99.45% |
Supply Ability:
10g |
| Release date:
2025/09/19 |
Product Introduction
Bioactivity
| Name | BIBF0775 |
| Description | BIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM). |
| Cell Research | The high-content cytotoxicity assay (kit I) was performed according to the manufacturer's instructions. HaCaT cells were cultured overnight in black 96-well plates, incubated for 24 h with each compound at different concentrations, and stained with cytotoxicity cocktail. Cells were fixed, washed, and scanned on the Cellomics ArrayScan II platform. Images were analyzed with the Cell Health image analysis algorithm. Cytotoxicity indices were calculated for each of the four parameters (cellular membrane integrity, nuclear fragmentation and density, and lysosomal mass) to indicate the percentage of cells outside of the normal range which was defined using a vehicle-treated reference cell population. |
| Kinase Assay | The inhibition of the kinase activity of TGFβRI was determined using the Promega Kinase-Glo kit according to the manufacturer's protocol in the presence of 600 nM ATP. N-terminally his-tagged human TGFβRI (aa 162-end) expressed in baculovirus and purified using nickel affinity chromatography was used at a final concentration of 0.03 μg/mL. The inhibition of the kinase activity of PDGFRR was determined using the Z0-LYTE assay technology according to the manufacturer's protocol. Full-length human PDGFRR (5.6 nM per assay) and the Tyr4 peptide (2 μM per assay) were obtained from Invitrogen, too. IC50 values were determined by the use of the Graph PadPrism software. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 11 mg/mL (22.24 mM), Sonication is recommended.
|
| Keywords | Transforming growth factor beta receptors | TGFβR1(ALK5) | TGF-β/Smad | TGF-β Receptor | TGFβ | TGFbeta/Smad | TGF-beta | TGFbeta | TGF-b/Smad | TGFb | Smad | Inhibitor | inhibit | BIBF-0775 | BIBF0775 | BIBF 0775 | Alk5 |
| Inhibitors Related | Entrectinib | Monocrotaline | DMH-1 | Hydrochlorothiazide | Chebulinic acid | Crizotinib | Chromenone 1 | Ceritinib | Pirfenidone | A 83-01 | Galunisertib | Alantolactone |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Liver Cancer Compound Library | TGF-beta/Smad Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:7681-15-4
$82.00 / 1mg
-
CAS:3934-86-9
$63.00 / 500mg
-
CAS:1053228-28-6
$30.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
![2,4,5-Trichloro-7H-pyrrolo[2,3-d]pyrimid](https://img.chemicalbook.com/ProductImageEN2/2025-10/Large/dc43ccad-67e3-4e53-8a58-200b35a9fc55.png)
United States